News Search Results
May 14, 2025, 07:00 ET CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate Updates
Alan Glicklich, M.D., to the Company's Board of Directors. Dr. Glicklich has more than 20 years of experience in the biotechnology industry and currently serves as Chief Medical Officer of Nuvig Therapeutics. Previously, he was Chief Medical Officer of Chinook Therapeutics.Other
More news about: CalciMedica, Inc.
May 14, 2025, 05:52 ET Noster research: Gut bacteria-derived molecule found to shrink fat cells and improve metabolism
(stearoyl-CoA desaturase 1), CPT1A (carnitine acyltransferase 1A), GPR (G protein-coupled receptor) About Noster Inc. Noster Inc. is a biotechnology company based in Kyoto, Japan. The company focuses on postbiotics—compounds produced by gut bacteria—to develop
More news about: Noster Inc
May 14, 2025, 03:30 ET Kaerus Bioscience's lead candidate KER-0193 granted Orphan Drug Designation and Rare Pediatric Drug Designation by U.S. FDA for treatment of Fragile X syndrome (FXS)
Phase 2 proof-of-concept study in FXS patients. About Kaerus Backed by Medicxi, Kaerus Bioscience Ltd is a clinical-stage biotechnology company committed to turning scientific advances into treatment realities for patients with rare genetic syndromes of neurodevelopment. Kaerus has
More news about: Kaerus Bioscience
May 14, 2025, 02:04 ET Julius Clinical and Peachtree BioResearch Solutions Merge to Form a Fully Integrated Global CRO with Increased CNS Capabilities
combines scientific leadership, operational excellence, and a global network of research sites to deliver tailored solutions for pharmaceutical, biotechnology, and partners. For more information, visit
More news about: Julius Clinical Research
May 13, 2025, 17:00 ET Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference
reach out to your respective H.C. Wainwright representative. About Nektar Therapeutics Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases.
More news about: Nektar Therapeutics
May 13, 2025, 17:00 ET Rgenta Therapeutics Presents Data from Proprietary RSwitch Technology Demonstrating Versatile, Tunable Transgene Expression in AAV-Delivered Gene Therapies with Orally Administered Small Molecules (RDrugs)
Mass., May 13, 2025 /PRNewswire/ -- Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA regulation for oncology and neurological disorders,
More news about: Rgenta Therapeutics
May 13, 2025, 16:06 ET Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 13, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase
More news about: Intensity Therapeutics Inc.
May 13, 2025, 16:05 ET INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights
MEETING, Pa., May 13, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious
More news about: INOVIO Pharmaceuticals, Inc.
May 13, 2025, 15:00 ET skinbetter science® Launches Even Intensive Skin Tone Correcting Serum, a Cutting-Edge Discoloration Technology for Stubborn Dark Marks
improvement in uneven skin tone4"skinbetter science continues to lead in innovation, now pairing their new b.r.y.t.e.r. biotechnology with their patented TAP technology," said Sonia Batra, MD, Board-Certified Dermatologist. "This serum delivers substantial
More news about: skinbetter science
May 13, 2025, 12:36 ET CellFE and Made Scientific Announce Strategic Collaboration to Advance Non-viral Gene Editing for T Cell Therapies
the global expertise and resources of GC Corporation of South Korea, a global leader in the pharmaceutical and biotechnology sectors. For media inquiries, please contact:CellFE: [email protected]
More news about: Made Scientific, Inc
May 13, 2025, 12:29 ET AAD mourns the loss of board chair Bob Shapiro
training, Shapiro became CEO and chairman of Monsanto, where he transformed the chemical company into a leader in biotechnology on a mission to improve people's lives through food and ag biotechnology. He was also chairman of the board at Pharmacia, launched NutraSweet as the first branded food ingredient, co-founded
More news about: Ad Astra Diagnostics, Inc.
May 13, 2025, 12:26 ET Granata Bio Announces Strategic Investment and Collaboration with Gedeon Richter to Expand U.S. Fertility Market Leadership
BOSTON, May 13, 2025 /PRNewswire/ -- Granata Bio ("Granata"), a U.S.-based biotechnology company focused on advancing fertility therapeutics, today announced a strategic partnership with Gedeon Richter Plc. ("Richter"), a global
More news about: Granata Bio
May 13, 2025, 11:59 ET Danforth Technology Company Launches Genome Editing Startup
Board is comprised of leading industry experts, including: Larry Gilbertson, PhD, former biotechnology leader at Monsanto and BayerJerry Hjelle, PhD, President, Hjelle AdvisorsJon
More news about: Donald Danforth Plant Science Center
May 13, 2025, 11:13 ET Scout Celebrates Third Consecutive MedTech Breakthrough Award
hybrid clinical meeting planning, patient payment, travel and logistics support, and virtual collaboration and education for top pharmaceutical and biotechnology companies. Learn more about our legacy at
More news about: Scout
May 13, 2025, 10:35 ET Small Cell Lung Cancer Summit Empowers Patients, Uniting Them with Researchers, Other Experts
The LiveLung Summit was supported by industry partners, Amgen, AstraZeneca, Boehringer Ingelheim, Catalyst Pharmaceuticals, Gilead, and Puma Biotechnology. For more information about the Summit, visit:
More news about: LiveLung
May 13, 2025, 10:01 ET Drug Device Combination Products Market worth US$379.17 billion by 2030 with 9.3% CAGR | MarketsandMarkets™
drug-device products across multiple therapeutic areas. Specifically, the company provides bespoke injection systems tailored for pharmaceutical & biotechnology firms, particularly those operating in diabetes management, growth modulation, and additional therapeutic domains. To enhance user experience in
More news about: MarketsandMarkets
May 13, 2025, 09:15 ET Illumina DRAGEN v4.4 powers clinical oncology research and multiomic applications
most accurate variant calling tool available for germline WGS testing. This was demonstrated in a peer-reviewed study published in Nature Biotechnology in October 2024, "
More news about: Illumina, Inc.
May 13, 2025, 09:00 ET Thryv Therapeutics to Share Recent Clinical Results and Participate in Upcoming Healthcare Investor Conferences
MONTREAL, May 13, 2025 /PRNewswire/ - Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing a series of novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for cardiovascular diseases, today announced its participation
More news about: Thryv Therapeutics Inc.
May 13, 2025, 09:00 ET Sollis Health Appoints Melanie Goldey to Board of Directors
Currently CEO of Tally Health, a biotechnology company advancing healthspan and longevity through cutting-edge testing and personalized interventions, Goldey has built a reputation for driving
More news about: Sollis Health
May 13, 2025, 08:41 ET Gallant Names Dr. Rebecca Windsor Director of Veterinary Affairs as Company Advances Its Off-the-Shelf Stem Cell Therapy for Cats
allant, an animal health biotechnology company pioneering off-the-shelf stem cell therapies for pets, announced that Rebecca Windsor, DVM, DACVIM, has joined
More news about: Gallant
May 13, 2025, 08:00 ET iNtRON Seeks a Strategic Partner to Explore the Promising Market for MRSA Decolonization
BOSTON, May 13, 2025 /PRNewswire/ -- iNtRON Biotechnology, Inc., a biotechnology company focused on developing innovative endolysin-based new biological drug for superbugs and unmet medical needs, today announced
More news about: iNtRON Biotechnology, Inc.
May 13, 2025, 07:05 ET REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II
which has been shown to correlate with neurocognitive manifestations of the disorder. ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field
More news about: REGENXBIO Inc.
May 13, 2025, 07:00 ET Leap Therapeutics Reports First Quarter 2025 Financial Results
Mass., May 13, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter of 2025. Leap
More news about: Leap Therapeutics, Inc.
May 13, 2025, 06:00 ET Genentech to Build First East Coast Manufacturing Plant in North Carolina
sciences company, having started the entire global biotechnology industrial revolution back in 1976," said William Bullock, senior vice president of economic and statewide development at the North Carolina Biotechnology Center. "A mere 8 years later, North
More news about: Economic Development Partnership of North Carolina
May 13, 2025, 06:00 ET Strategic Partnership | Sanyou Bio and TransRecoBio Forge Strategic Alliance to Build a New Ecosystem for the Full Industry Chain
Recently, Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. ("Sanyou Biopharmaceuticals") and TransRecoBio (Wenzhou) Biotechnology Co., Ltd. ("TransRecoBio") officially signed a strategic cooperation agreement. The two companies will integrate their core strengths in antibody
More news about: Sanyou Bio